New findings from two studies support substantial benefit of Pradaxa®
- Details
- Category: Boehringer Ingelheim
Today, the New England Journal of Medicine published findings from the RE-MEDYTM and RE-SONATETM trials investigating Pradaxa® (dabigatran etexilate) in the long-term prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). The results demonstrate that Pradaxa® 150 mg twice daily is an effective option with a favourable safety profile for the extended prevention of recurrence of these venous blood clots (known as venous thromboembolism or VTE) after a first event.*
UCB announces regulatory filings for Cimzia® (certolizumab pegol)
- Details
- Category: UCB
UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).
Sanofi New Drug Application for lixisenatide accepted for review by FDA
- Details
- Category: Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus.
ViiV Healthcare announces FDA priority review designation for dolutegravir
- Details
- Category: GlaxoSmithKline
ViiV Healthcare announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection, in combination with other antiretroviral agents, in adults and adolescents.
Accelerating focus on the patient
- Details
- Category: UCB
With its "crossover year" delivered in 2012 and UCB's new core medicines now driving company growth, UCB's transformation into a biopharma company is complete. UCB is now entering an important new phase of revenue growth with no major patent expiry expected until the end of the decade.
Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced it has entered into a three-year collaboration agreement with Reckitt Benckiser Group plc (LSE: RBL) for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil.
Sanofi delivers solid 2012 results despite patent expirations
- Details
- Category: Sanofi
In the fourth quarter of 2012, Sanofi (EURONEXT: SAN and NYSE: SNY) generated sales of €8,526 million, an increase of 0.2% on a reported basis. Exchange rate movements had a positive effect of 1.9 percentage points primarily reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Chinese Yuan, Mexican Peso, Australian dollar and British Pound against the Euro.
More Pharma News ...
- Novo Nordisk increased operating profit by 32% in 2012
- Roche delivers strong 2012 results
- AstraZeneca fourth quarter and full year results 2012
- GSK response to news article in The Guardian on UK legal proceedings related to Avandia
- Bristol-Myers Squibb reports fourth quarter financial results
- Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
- Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013